ASH 2022 Conference Coverage

 

ASH 2022 Conference Coverage
Avatar

Selected Updates in MDS

By ASH 2022 Conference Coverage FEATURING Amer Zeidan
By ASH 2022 Conference Coverage FEATURING Amer Zeidan
468 views
February 14, 2023
0 Comments
Login to view comments. Click here to Login

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay
MDS and MPN
18:24
ASH 2022 Conference Coverage

Ropeginterferon Alfa-2b vs. Standard Therapy for Low-Risk Pts With P…

Feat. T. Barbui
05:09
ASH 2022 Conference Coverage

MEDALIST Study: Multiple Episodes of Transfusion Independence With L…

Feat. U. Platzbecker
31:13
ASH 2022 Conference Coverage

Selected Updates in MDS

Feat. A. Zeidan
08:24
ASH 2022 Conference Coverage

Phase 2 FIGHT-203 Study: Pemigatinib in Pts With Myeloid/Lymphoid Ne…

Feat. A. Vannucchi
09:27
ASH 2022 Conference Coverage

MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intole…

Feat. M. McMullin
03:41
ASH 2022 Conference Coverage

ASH 2022: Venetoclax Combined With Cladribine, Idarubicin, Cytarabin…

Feat. G. Borthakur
06:04
ASH 2022 Conference Coverage

ASH 2022 Real-World Validation of Molecular International Prognostic…

Feat. M. Della Porta
11:00
ASH 2022 Conference Coverage

ASH 2022: Management of Accelerated and Blast-Phase MPN

Feat. R. Rampal
10:14
ASH 2022 Conference Coverage

ASH 2022: Navitoclax and Ruxolitinib in JAKi-Naïve Patients With MF …

Feat. F. Passamonti
27:09
ASH 2022 Conference Coverage

ASH 2022: What Is Complete HLA Match in 2022?

Feat. S. Spellman
06:34
ASH 2022 Conference Coverage

ASH 2022 Outcomes of Patients With Accelerated/Blast-Phase MPNs in t…

Feat. A. Patel
09:54
ASH 2022 Conference Coverage

ASH 2022 Phase II Study of Myeloablative 8/8- or 7/8-Matched AlloSCT…

Feat. A. Hoover
06:06
ASH 2022 Conference Coverage

Synergistic Activity of Luspatercept and Erythroid Stimulating Agent…

Feat. R. Komrokji
06:55
ASH 2022 Conference Coverage

Luspatercept for Treatment of LR-MDS: Real World Data Replicates MED…

Feat. R. Komrokji
07:02
ASH 2022 Conference Coverage

ASH 2022 Phase 1 Results of the First-in-Class CXCR1/2 Inhibitor SX-…

Feat. D. Sallman
10:30
ASH 2022 Conference Coverage

ASH 2022 Primary Results of STIMULUS-MDS1: A Randomized, Double-Blin…

Feat. A. Zeidan
06:10
ASH 2022 Conference Coverage

Phase 3b, Single-Arm, Multicenter Study to Assess the Efficacy, Safe…

Feat. J. Mascarenhas
08:11
ASH 2022 Conference Coverage

Validation of 2022 WHO & ICC Classifications in MDS - An Analysi…

Feat. S. Ball
08:02
ASH 2022 Conference Coverage

ASH 2022 Results From Phase III BMT CTN 1703: Post-Transplant Cyclop…

Feat. S. Holtan
11:40
ASH 2022 Conference Coverage

ASH 2022 Efficacy & Safety of Add-On Parsaclisib to Ruxolitinib …

Feat. A. Yacoub
08:57
ASH 2022 Conference Coverage

ASH 2022 Impact of Allelic State on Overall Survival in TP53-Mutant …

Feat. J. Bewersdorf
11:20
ASH 2022 Conference Coverage

Updated Results From the Momentum Phase 3 Study of Momelotinib vs. D…

Feat. A. Gerds